- The FDA grants full approval of Roche's (OTCQX:RHHBY) Venclexta (venetoclax), combined with chemo, for the treatment of newly diagnosed acute myeloid leukemia (AML).
- The agency signed off on accelerated approval in November 2018.
- The company is developing and commercializing the BCL-2 inhibitor with AbbVie (NYSE:ABBV).
- https://seekingalpha.com/news/3623116-fda-fully-approves-roches-venetoclax-for-first-line-acute-myeloid-leukemia
Monday, October 19, 2020
FDA fully approves Roche's venetoclax for first-line acute myeloid leukemia
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.